RASSF1A (RAS-association domain family 1, isoform A) is a newer tumor suppressor that binds to and stabilizes microtubules as well as induces M-phase cell cycle arrest. Several other proteins that interact with and stabilize microtubules also undergo mitotic phase phosphorylation to regulate microtubule dynamics and M-phase cell cycle progression. Currently, however, there is a paucity of information regarding the phosphorylation status of RASS-F1A and its regulation during mitosis. In this study, for the first time, we demonstrate that Aurora-A is a RASSF1A kinase and, to the best of our knowledge, this is also the first study reporting the identification of a kinase for RASSF1A. We show that the mitotic kinase Aurora-A directly interacts with and phosphorylates RASSF1 and that RASSF1A is phosphorylated by Aurora-A during mitosis. These findings therefore link an important oncogenic mitotic kinase to regulate RASSF1A tumor suppressor. Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Our results further demonstrate that Aurora-A overexpression also interferes with RASSF1A-mediated growth suppression. In view of our results, we propose that Aurora-A-mediated phosphorylation of RASSF1A is a novel mechanism that regulates the ability of this tumor suppressor to interact with microtubules and modulate M-phase cell cycle progression.
Introduction
Recent studies have shown that tumor suppressor RASSF1A (RAS-association domain family 1, isoform A) plays an important role in human tumorigenesis. In a variety of tumors, frequent loss of RASSF1A gene expression has been reported to occur due to epigenetic alterations involving promoter hypermethylation (Dammann et al., 2000) . We have demonstrated that introduction of exogenous RASSF1A in non-expressing tumor cells causes growth suppression (Rong et al., 2004) . RASSF1A is believed to mediate tumor cell growth via various mechanisms including negative regulation of cell cycle both at G 1 and M phases of the cell cycle. For example, RASSF1A has been reported to induce G 1 arrest by inhibiting cyclin D1 accumulation (Shivakumar et al., 2002) , whereas it mediates M-phase arrest via multiple mechanisms. For instance, Song et al. (2004) have reported that RASSF1A appears to mediate M-phase arrest via modulating the anaphase-promoting complex (APC), which is a multisubunit E3 ubiquitin ligase needed to trigger the degradation of M-phase onset proteins. We also demonstrated that RASSF1A is a microtubule-interacting protein that negatively regulates cell cycle progression at the M phase via its ability to interact with microtubules. RASSF1A not only interacts with microtubules but also stabilizes microtubules (Rong et al., 2004) . RASSF1A interacts with microtubules via its central basic region containing amino acids 120-288 (Rong et al., 2004) . It is known that during M phase of the cell cycle microtubules rapidly assemble and disassemble to generate mitotic spindles, which ensure equal divisions of all sister chromatids into daughter cells (Wittman et al., 2001) . This process prevents premature anaphase before all kinetochores have been properly captured by the mitotic spindles. It appears that the ability of RASSF1A to interact with and stabilize microtubules is associated with its potential to induce M-phase arrest (Rong et al., 2004) . Such findings suggest that RASS-F1A regulation of microtubule stability appears to play an important role in RASSF1A-mediated M-phase cell cycle arrest.
Previous studies have shown that microtubule-binding/associated proteins (MAPs) such as MAP2 and MAP4 are phosphorylated during mitosis (Faruki et al., 1992; Ookata et al., 1997) . Phosphorylation is a critical event regulating these MAPs as it causes their dissociation from microtubules and thereby facilitates M-phase cell cycle progression.
RASSF1A is a newly identified microtubule-interacting/stabilizing protein, which modulates mitotic arrest. However, whether RASSF1A is also phosphorylated during mitosis is an important issue that remains to be fully elucidated. If RASSF1A is indeed modulated via phosphorylation during mitosis then identification of the kinase(s) that phosphorylate RASSF1A will prove very valuable to understand better the function and regulation of this newer tumor suppressor. We undertook this study to investigate these issues and present data to demonstrate, for the first time, that RASSF1A is phosphorylated by a mitotic kinase named Aurora-A. We also present evidence that Aurora-A-mediated phosphorylation modulates RASS-F1A's ability to interact with microtubules and induce mitotic arrest.
Results

RASSF1A is a phosphorylated protein
First, we performed intracellular 32 P-labeling to determine whether RASSF1A is a phosphorylated protein.
Supplementary Figure 1A shows that the 32 P-labeled myc-tagged RASSF1A was detected only when immunoprecipitations were performed with anti-myc-tag antibody but not with control IgG. Treatment with alkaline phosphatase (CIP, a pan-phosphatase) of the cell lysates carrying myc-tagged RASSF1A clearly diminished the 32 P-specific RASSF1A signal, demonstrating de-phosphorylation of RASSF1A by this phosphatase. Overall expression of exogenous myc-RASSF1A was confirmed by western blotting (Supplementary Figure 1A , lower panel). Next, we transiently expressed exogenous HAtagged RASSF1A in 293T cells and analysed its migration pattern in the presence and absence of phosphatase inhibitors. Results in Supplementary Figure  1B indicate that phosphorylated RASSF1A was also detected as a slow migrating form in cell lysates treated with phosphatase inhibitor PPI but not in untreated lysates or those treated with alkaline phosphatase. Given that PPI would prevent de-phosphorylation of RASS-F1A, the slow migrating form appears to be the phosphorylated RASSF1A. Together, these results demonstrate that least proportion of RASSF1A exists in the phosphorylated state.
Identification of Aurora-A as a RASSF1A kinase Next, we performed the in vitro in-gel kinase assay to identify the kinase(s) that is/are responsible for RASSF1A phosphorylation. As shown in Figure 1a , RASSF1A phosphorylation by the candidate kinase was significantly enhanced in cells synchronized in the mitotic phase either by nocodazole (N) or taxol (T) treatment when compared to untreated (C) cells. Western analysis of anti-b-actin demonstrated equal amounts of protein input in these experiments ( Figure 1a ). Bovine serum albumin (BSA) was used as a mock substrate in parallel experiments. As also shown in Figure 1a , enhanced activity of the candidate kinase was evident only when purified RASSF1A was used as a substrate but not with BSA (right panel). We further investigated whether activity of the candidate kinase was specific in the mitotic phase or for drug treatment with taxol and nocodazole. To do that, we used the double thymidine block plus the mitotic shake-off method to enrich mitotic cell population. Figure 1b (upper panels) shows that the shake-off method significantly enriched the mitotic cell population. The results of in-gel kinase assay performed on cells enriched in the mitotic phase or G 1 phase indicated that RASSF1A phosphorylation by the candidate kinase was significantly enhanced in the mitotic cell population when compared to the G 1 population (Figure 1b , lower panels). According to literature and database searches, the molecular mass (45.8 kDa) of human Aurora-A mitotic kinase (Crosio et al., 2002) matched closely to that of the candidate kinase for RASSF1A. Figure 1c shows the consensus sequence of Aurora-A phosphorylation sites in some of its known substrates, and we noted the RASSF1A amino-acid sequence at position 198-205 (RRRTSFY) to be very similar to the Aurora-A phosphorylation consensus motif. To investigate whether Aurora phosphorylates RASSF1A, we knocked down Aurora-A expression via RNAi and the in-gel kinase assays were performed to determine the phosphorylation status of RASSF1A. Figure 1d (upper panel) shows that RASSF1A phosphorylation was significantly diminished upon Aurora-A knockdown. Western blotting showed that RNAi specifically knocked down Aurora-A expression ( Figure 1d , lower panel). Together these results indicate Aurora-A to be the potential kinase for RASSF1A.
We also performed the in vitro kinase assay to determine the ability of Aurora-A to phosphorylate RASSF1A. Figure 2a indicates that the immunoprecipitated endogenous Aurora-A strongly phosphorylated the purified RASSF1A but such phosphorylation was not noted with control IgG. Western blotting confirmed that only Aurora-A-specific antibody immunoprecipitated the endogenous Aurora-A while IgG did not (Figure 2a, lower panel) . In addition, Aurora-A kinase dead mutation (K162R) (Katayama et al., 2001) significantly reduced its ability to phosphorylate RASS-F1A (Figure 2a, right panel) , which further highlights the specificity of Aurora-A-mediated RASSF1A phosphorylation. Expression of exogenous wild-type and mutant Aurora-A was confirmed by western blotting (Figure 2a, right panel) . Next, we sought to investigate whether RASSF1A phosphorylation increases during mitosis. As shown in Figure 2b , Aurora-A-mediated RASSF1A phosphorylation was strongly enhanced in nocodazole-arrested M-phase cells (Figure 2b , top panel, lane 3) when compared to asynchronous cells (untreated). Collectively, these results demonstrate that Aurora-A is a RASSF1A kinase.
RASSF1A interacts with Aurora-A
We also investigated whether Aurora-A was capable of interacting with RASSF1A and as shown in Figure 3a (upper panel), endogenous Aurora-A co-immunoprecipitated with GFP-tagged RASSF1A (lane 1). Such interactions were not seen in lysates immunoprecipitated with control IgG (lane 2) or in cell lysates expressing the GFP alone (lane 3). Figure 3a (lower panel) shows the expression of exogenous GFP-tagged RASSF1A and GFP alone in these cells. To confirm that Aurora-A directly interacts with RASSF1A, we utilized purified S-tagged RASSF1A and Aurora-A recombinant proteins in protein pull-down assays. Results presented in Figure 3b demonstrate that indeed Aurora-A directly interacts with RASSF1A. Aurora-A is known to associate with centrosomes at the mitotic poles as well as the adjacent mitotic spindles (Carmena and Earnshaw, 2003) . We, therefore, investigated the subcellular localization of Aurora-A in relation to RASSF1A, and results in Figure 3c show that Aurora-A co-localizes with RASSF1A at or near centrosomes/ spindle poles in mitotic cells. These results, therefore, indicate that RASSF1A and Aurora-A appear to interact with each other at or near centrosomes/spindle pools during mitosis.
Aurora-A phosphorylates RASSF1A at Thr202 and Ser203 RASSF1A harbors a putative Aurora-A phosphorylation consensus motif 'RRRTSFY' at position 198-205 (Figures 1c and 4a ). To delineate whether Ser202 and/or Thr203 within 'RRRTSFY' serve as potential phosphorylation site(s) for Aurora-A, we mutated these residues and purified the mutant and wild-type RASSF1A proteins (Figure 4a ) for in vitro kinase assay.
Results shown in Figure 4b indicate that single-aminoacid substitution of Thr202 to Ala202 or Ser203 to Ala203 did not significantly affect Aurora-A-mediated RASSF1A phosphorylation, whereas double-point mutations on both Thr202 and Ser203 (T202A/S203A) completely abolished Aurora-A-mediated phosphorylation of RASSF1A. These results indicate that either Thr202 or Ser203 is essential for Aurora-A-mediated phosphorylation of RASSF1A. To investigate whether Aurora-A directly phosphorylates RASSF1A, we performed Aurora-A kinase assays using the purified β-actin
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Figure 1 (a) The in-gel kinase assay detects a candidate kinase (B46 kDa) for RASSF1A. C; untreated/unsynchronized cells, T; synchronized by taxol, N; synchronized by nocodazole. (b) Flow cytometry analysis of synchronized and unsynchronized 293T cells. Cells were synchronized by the mitotic 'shake-off' method and G 1 or M phase-enriched cells were prepared as described in Supplementary Information. In-gel kinase assay used either the purified RASSF1A or BSA as a substrate. (c) The Aurora-A phosphorylation sites in three known Aurora-A substrates are compared with the putative Aurora-A phosphorylation sites in RASSF1A. (d) Aurora-A-specific siRNA affects the B46-kDa kinase-mediated phosphorylation of RASFF1A. RASSF1A, RASassociation domain family 1, isoform A.
Aurora-A is a mitotic kinase for RASSF1A R Rong et al recombinant Aurora-A as well as the recombinant wildtype and phosphorylation-defective (T202A/S203A) mutant RASSF1A. As shown in Figure 4c , recombinant Aurora-A directly phosphorylates the purified wild-type RASSF1A but not the double-mutant form (T202A/ S203A). It is interesting that based on our previous studies (Rong et al., 2004) both residues reside within the microtubule-interacting region of RASSF1A.
Phosphorylation-mimicking mutant RASSF1A lacks the ability to interact with microtubules and induce M-phase cell cycle arrest To investigate whether RASSF1A phosphorylation status affects RASSF1A interactions with microtubules, we generated two GFP-tagged RASSF1A double mutants ( Figure 5a ). Wild-type and mutant RASSF1A constructs were then transiently introduced into 293T cells for assessing their ability to interact with microtubules. Results in Figure 5b indicate that the GFP-tagged wildtype RASSF1A largely overlapped with anti-a-tubulin immunostaining (panel 2), a finding which is consistent with our previous results (Rong et al., 2004) ) did not overlap with a-tubulin immunostaining pattern but rather appeared punctuate throughout the cytosol. These results, therefore, suggest that the phosphorylationmimicking mutant RASSF1A did not appear to interact with microtubules ( Figure 5b, panel 3) . We also performed co-immunoprecipitation assay to determine further whether phosphorylation-mimicking (GFP-F1A-E 202 E 203 ) mutant-RASSF1A was indeed unable to interact with microtubules. Figure 5c shows that while the wild-type GFP-RASSF1A interacted with a-tubulin, the phosphorylation-mimicking (GFP-F1A-E 202 E 203 ) mutant did not, which confirmed that this mutant was unable to interact with microtubules.
We also investigated the biological effects of phosphorylation-null and phosphorylation-mimicking mutations on the ability of RASSF1A to induce M-phase arrest. To that end, 293T cells were transiently transfected with the constructs expressing these mutants or wild-type RASSF1A and cell cycle profiles of each transfectant were determined by FACS analyses. Table 1 shows representative results and consistent with our previous findings (Rong et al., 2004) , expression of wildtype GFP-tagged RASSF1A increased the M-phase (4N) population at each time point when compared with cells expressing GFP alone. However, phosphorylationmimicking mutation (E202/E203) almost completely abolished the ability of RASSFA1 to induce M-phase arrest, whereas phosphorylation-null mutant (A202/ A203) behaved similar to wild-type RASSF1A. These findings led us to propose that dephosphorylation of RASSF1A at Thr202/Ser203 residues would promote its interaction with microtubules with ensuing M-phase . Expression of the exogenous wild-type or mutant Aurora-A proteins was confirmed by western blotting using anti-GFP antibody (lower right panel). (b) Aurora-A phosphorylates RASSF1A during mitosis. GFP-tagged Aurora-A or GFP alone was transiently expressed in 293T cells and cells were treated with nocodazole to enrich the mitotic phase population. In vitro kinase assay was performed using the purified RASSF1A as a substrate. Expression of exogenous GFP-tagged Aurora-A was confirmed by western blotting using anti-GFP antibody (lower panel).
RASSF1A, RAS-association domain family 1, isoform A.
Aurora-A is a mitotic kinase for RASSF1A R Rong et al arrest while phosphorylation of these residues would cause it to disassociate from microtubules and thereby permit progression from M to next phase of the cell cycle.
Aurora-A interferes with RASSF1A-mediated growth suppression We also studied the effect of overexpression of Aurora-A on RASSF1A-mediated growth suppression using colony formation assay. Table 2 shows that expression of exogenous RASSF1A significantly inhibited colony formation (combination 3) but overexpression of GFP- Aurora-A is a mitotic kinase for RASSF1A R Rong et al transfectants (Supplementary Figure 2) . Taken together, these results suggest that Aurora-A is capable of interfering with RASSF1A-mediated growth suppression and that it may do so via its ability to phosphorylate RASSF1A.
Discussion
In this study, we have identified Aurora-A as a kinase for tumor suppressor RASSF1A. There is a paucity of information on the phosphorylation status of RASS-F1A in the literature. In this study, for the first time, we demonstrate that Aurora-A is a RASSF1A kinase. To the best of our knowledge, this is also the first study reporting the identification of a kinase for RASSF1A.
Our present results indicate that Aurora-A appears to phosphorylate RASSF1A at Thr202 or Ser203 and a single substitution of Thr202 to Ala or Ser203 to Ala does not significantly affect Aurora-A-mediated RASS-F1A phosphorylation. However, similar substitution of both residues creating a double mutant (T202A/S203A) completely abolishes Aurora-A-mediated RASSF1A phosphorylation. Owing to close proximity of these two residues, it is possible that only one of the two residues is predominantly phosphorylated by Aurora-A in the wild-type conformation; when the predominant phospho-residue is mutated, the adjacent residue could become phosphorylated. Future studies will enable us to elucidate as to which one of the two is the predominant phospho-residue in the wild-type protein. Interestingly, we also found that substitutions of Ser202/S203 residues with Glu202/Glu203, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interaction with microtubules and abolish its ability to induce M-phase arrest. These results suggest that Aurora-Amediated RASSF1A phosphorylation appears to play an important role in regulation of RASSF1A-microtubule interactions and RASF1A-mediated M-phase cell cycle arrest. We previously demonstrated that RASSF1A interacts with and stabilizes microtubules (Rong et al., 2004) . RASSF1A overexpression was found to induce mitotic arrest, and RASSF1A mutants were unable to interact with microtubules and also failed to induce mitotic arrest (Vos et al., 2004) . Those results indicated that microtubule interactions and stabilization were critical for RASSF1A to induce mitotic arrest. Our present results indicate that the mitotic kinase Aurora-A phosphorylates RASSF1A during mitotic phase of the cell cycle and modulates its ability to induce mitotic arrest. Several previous studies have reported that a number of microtubule-associated proteins that also stabilize microtubules are regulated by mitotic kinases in a similar fashion. For example, Polo-like kinase (Plk), a mitotic kinase, has been found to phosphorylate the translationally controlled tumor protein (TCTP), a microtubule-binding/stabilizing protein that regulates spindle formation (Yarm, 2002) . Evidence suggests that Plk-induced TCTP phosphorylation diminishes the microtubule-stabilizing function of TCTP (Yarm, 2002) . The tumor suppressor adenomatous polyposis coli (APC) has also been reported to be a microtubuleinteracting/stabilizing protein and its interactions with Abbreviations: A 202-203 , phosphorylation-null mutant in which Thr202/ Ser203 are replaced with Ala202/Ala203; E [202] [203] , phosphorylationmimicking mutant in which Thr202/Ser203 is replaced with Glu202/ Glu203; RASSF1A, RAS-association domain family 1, isoform A; WT, wild type. a 293T cells seeded on 100 mm plates were transiently transfected with 10 mg of plasmids expressing either GFP alone or various GFP-tagged wild-type or the indicated mutant forms of RASSF1A. Cells were fixed at 24, 48 and 72 h time point following transfection and analysed for the DNA content of the GFP-expressing cells using flow cytometry as we have previously described (Rong et al., 2004) . The presented values represent the means of three independent experiments. Abbreviations: RASSF1A, RAS-association domain family 1, isoform A. MCF-7 human breast cancer cells were co-transfected with the indicated vectors. The transfected cells were selected in the presence of hygromycin B for 14 days and the numbers of colonies in the culture plates were counted.
Aurora-A is a mitotic kinase for RASSF1A R Rong et al microtubules are regulated by the mitotic kinase p34/ cdc2 during mitosis (Trzepacz et al., 1997) . Interestingly, p34/cdc2-induced APC phosphorylation has been found to disrupt APC and microtubule interactions, a finding that highlights the importance of phosphorylation in regulation of APC interactions with microtubules (Trzepacz et al., 1997) . MAP4 is another important microtubule-binding protein that has been found to be phosphorylated by mitotic kinases including p34/cdc2 and microtubule-affinity regulating kinases (Illenberger et al., 1996; Ookata et al., 1997) . Evidence suggests that MAP4 phosphorylation induced by these mitotic kinases causes MAP4 to dissociate from microtubules and thereby increase microtubule dynamics during mitosis (Illenberger et al., 1996) . Furthermore, phosphorylation-deficient MAP4 is unable to dissociate from microtubules, which leads to impaired chromosomal segregation during anaphase (Shiina and Tsukita, 1999) . Thus, as noted above, several lines of published evidence highlight the phosphorylation-mediated regulation of microtubule-binding/stabilizing proteins to be an important and necessary event for normal chromosomal segregation and cell division. RASSF1A is a newer microtubule-binding and stabilizing protein that, based on our present findings, is phosphorylated via mitotic kinase Aurora-A. Our current results indicate that Aurora-A-mediated RASS-F1A phosphorylation is evident predominantly during mitotic phase but not in G 1 phase of the cell cycle. Given that Aurora-A is mostly active during mitosis, our results, therefore, suggest that RASSF1A phosphorylation also occurring during mitosis appears to be temporally linked to Aurora-A activation. Furthermore, phosphorylation-based regulation of RASSF1A by this mitotic kinase appears to occur in a manner similar to regulation of other MAPs via their respective mitotic kinases. Our identification of putative Aurora-A phosphorylation sites at residues Thr202/Ser203, residing within the known microtubule-association domain of RASSF1A, is an important finding. This piece of data would suggest that Aurora-A-mediated phosphorylation of these residues may interfere with RASSF1A and microtubule interactions. In fact, our demonstration that the RASSF1A mutant (E202/E203) mimicking constitutive phosphorylation is unable to interact with microtubules and induce mitotic arrest appears to support this notion. Thus, based on our results, we propose that Aurora-A-mediated modification of RASSF1A would prevent RASSF1A from interacting with microtubules and thereby, restrain RASSF1A's effect to control mitotic cell progression.
We also demonstrate that overexpression of Aurora-A interferes with RASSF1A-mediated growth suppression. Aurora-A is one of the major mitotic kinases that are also overexpressed in a variety of human malignancies. Increased expression of Aurora-A has been reported to cause abnormal chromosomal segregation and aneuploidy (Zhou et al., 1998; Meraldi et al., 2002) . Interestingly, RASSF1A deficiency by RASSF1A-specific siRNA results in genomic instability and gives rise to aneuploidy (Song et al., 2004) . Our present study, therefore, raises an important question as to whether Aurora-A-mediated genomic instability is linked to the loss of RASSF1A function; further investigations are needed to address this issue. Previous studies have also implicated the role of Aurora-A in oncogenic transformation. For example, overexpression of Aurora-A has been reported to induce cellular transformation in NIH3T3 fibroblasts (Zhou et al., 1998) . Increased expression of Aurora-A has also been found to promote cell proliferation in esophageal cancer cells (Wang et al., 2006) . Our present results indicate that overexpression of Aurora-A markedly interferes with RASSF1A-induced growth suppression. It is possible that Aurora-A may achieve its oncogenic potential, in part, by negatively regulating RASSF1A via phosphorylation. However, Aurora-A does not completely block RASS-F1A-induced growth suppression, which could occur due to multiple reasons. For example, RASSSF1A has been reported to induce G 1 and M arrests as well as apoptosis (Shivakumar et al., 2002; Rong et al., 2004) and RASSF1A-mediated growth suppression could result due to combination of all of its functions. It is possible that Aurora-A, as a mitotic kinase, is capable of only interfering with RASSF1A-induced mitotic arrest but not G 1 arrest or apoptosis. Further studies are obviously needed and will likely provide additional insights into the aforementioned issues.
In summary, our present studies have provided valuable information about the regulation and function of RASSF1A and have laid the groundwork for future in-depth studies to further dissect the molecular functions of this important tumor suppressor.
Materials and Methods
Plasmid constructs, reagents and cell culture conditions Detailed information is provided in the Supplementary Information.
Immunoprecipitations, S-tag protein pull-down assays
Immunoprecipitations were performed as we have described previously (Rong et al., 2004) . For S-tag protein pull-down assay, S-tag alone and purified S-tag RASSF1A proteins were first immobilized onto S-protein conjugated agarose beads then mixed with recombinant active Aurora-A kinase. After extensive washes, the bead-bound proteins were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Cell cycle analysis
Cell cycle analyses were performed as we have previously described (Rong et al., 2004) .
In vitro kinase assay, in-gel kinase assay and cell synchronization Details on in-gel kinase assays, Aurora-A in vitro kinase assays and cell synchronization are provided in the Supplementary Information.
Aurora-A RNAi
The sequences for Aurora-A siRNA are 5 0 -AUGCCCUGU CUUAC UGUCAUU-3 0 and 5 0 -UGACAGUAAGACAGGG CAUUU-3 0 (Dharmacon Research Inc., Lafayette, CO, USA). (Kufer et al., 2002) .
